Sodium-Glucose Cotransporter-2 Inhibitors Across the Glycemic Spectrum: Cardiovascular and Renal Outcomes With Mechanistic Insights - Cureus

Sodium-Glucose Cotransporter-2 Inhibitors Across the Glycemic Spectrum: Cardiovascular and Renal Outcomes With Mechanistic Insights – Cureus

March 12, 2026

Sodium-Glucose Cotransporter-2 Inhibitors Across the Glycemic Spectrum: Cardiovascular and Renal Outcomes With Mechanistic Insights CureusSGLT2 Inhibitors: Electrolyte, Water Balance, and Stone Prevention Benefits Beyond Metabolic Effects FrontiersSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Non-diabetic Conditions Beyond Heart Failure and Chronic Kidney Disease: Emerging Evidence, Mechanisms, and Practical Considerations CureusSGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis ConexiantWhat are Benefits and Risks of SGLT2 Inhibitors in Diabetic Kidney Disease? Medical Dialogues